Is DYAX a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

380 people get DYAX articles and Market Currents by email alert.

Get email alerts on DYAX »

HEADLINES:

Dyax HAE Allies℠ Awards Program Launches on Second Annual Hereditary Angioedema (HAE) Day – a Global Event to Raise Awareness of HAE

Business Wire (Thu, 8:30AM)
Dyax Announces $30 Million Offering

Business Wire (May 13, 2013)
Despite Poor Quarter, ViroPharma's Commercial And Pipeline Progress Continue
PropThink • Fri, May 3
Dyax Corp. to Participate in the Needham Healthcare Conference

Business Wire (Apr 29, 2013)
Dyax Corporation's CEO Discusses Q1 2013 Results - Earnings Call Transcript
Thu, Apr 25
Dyax Corp. Announces First Quarter 2013 Financial Results

Business Wire (Apr 25, 2013)
Dyax Corp. to Host First Quarter 2013 Earnings Call and Webcast

Business Wire (Apr 18, 2013)
ViroPharma: Generic Concerns Overblown, Pipeline Will Bring Revenue Diversity
PropThink • Wed, Apr 3
Dyax Corp. to Participate in the 25th Annual ROTH Conference

Business Wire (Mar 12, 2013)
Dyax Announces Management Change

Business Wire (Mar 8, 2013)
Dyax Presents DX-2930 Data at the 2013 American Academy of Allergy, Asthma and Immunology Annual Meeting

Business Wire (Feb 25, 2013)
Dyax Corp. to Participate in Upcoming 2013 Healthcare Conferences

Business Wire (Feb 20, 2013)
Dyax's CEO Discusses Q4 2012 Results - Earnings Call Transcript
Wed, Feb 13
Dyax Corp. Announces Fourth Quarter and Full Year 2012 Financial Results

Business Wire (Feb 13, 2013)
Small Pharma Watch List: Week Of February 11th, 2013
Chemistfrog • Mon, Feb 11 • 4 Comments
China Biotech In Review: Cardinal Health Uses M&A To Add Drug Distribution Reach
ChinaBio Today • Sun, Feb 10
Pending Q4 Results: Dyax Partnerships Could Yield Sustained Growth For Investors
Chemistfrog • Fri, Feb 8 • 3 Comments
Dyax Corp. and CVie Therapeutics Announce Partnership to Develop and Commercialize KALBITOR® (ecallantide) for Hereditary Angioedema (HAE) and Other Angioedema Indications in China, Hong Kong and Macau

Business Wire (Feb 7, 2013)
Dyax Corp. to Participate in the Leerink Swann Global Healthcare Conference

Business Wire (Feb 6, 2013)
Dyax Corp. to Host Fourth Quarter and Year End 2012 Earnings Call and Webcast

Business Wire (Feb 5, 2013)

To learn more about Seeking Alpha Pro, click here.

Pending Q4 Results: Dyax Partnerships Could Yield Sustained Growth For Investors
Chemistfrog • Fri, Feb 8 • 3 Comments
Dyax And ViroPharma: An Overview Of HAE Space
LifeSci Advisors • Tue, Sep 18, 2012

Despite Poor Quarter, ViroPharma's Commercial And Pipeline Progress Continue
PropThink • Fri, May 3
ViroPharma: Generic Concerns Overblown, Pipeline Will Bring Revenue Diversity
PropThink • Wed, Apr 3
Small Pharma Watch List: Week Of February 11th, 2013
Chemistfrog • Mon, Feb 11 • 4 Comments
China Biotech In Review: Cardinal Health Uses M&A To Add Drug Distribution Reach
ChinaBio Today • Sun, Feb 10
5 Biotechs With Short Squeeze Potential Hitting New 52 Week Highs
Heisenberg Principle • Tue, Dec 11, 2012 • 1 Comment
4 Cash-Heavy Biotech Stocks That Analysts Rate As Strong Buy
ZetaKap • Tue, Aug 21, 2012 • 1 Comment
2 Micro Cap Biotech Stocks Ready To Soar
Connor Gach • Wed, Aug 1, 2012 • 4 Comments
Micro Cap Biotech Stocks Being Accumulated By The World's Largest Money Managers
GuruFundPicks • Wed, Jul 11, 2012 • 9 Comments
7 Highly Liquid Stocks Under $5 On Winning Streaks
Kapitall • Wed, Jul 4, 2012 • 3 Comments
3 Outperforming Micro Caps Under $5 On Winning Streaks
Kapitall • Tue, Jun 5, 2012
8 Biotechnology Stocks With Good Liquidity That Analysts Rate As Buy
ZetaKap • Fri, May 25, 2012
GE: A Winning Stock Right Now
ValueMax • Tue, Apr 10, 2012 • 7 Comments
Small Biotech Companies With Big Pipelines
ScriptVolume • Thu, Feb 23, 2012 • 8 Comments
14 Rallying Biotech Stocks Being Snapped Up By Insiders
Kapitall • Thu, Feb 2, 2012 • 1 Comment
Key Companies And Products In The Market To Treat The Orphan Disease Hereditary Angioedema
Smith On Stocks • Thu, Sep 8, 2011 • 2 Comments
10 Biotech Stocks Being Dumped By Big Money Managers
Kapitall • Tue, Aug 30, 2011 • 1 Comment
Accipiter Capital's Most Favorite Stock Picks
Insider Monkey • Sun, Jun 5, 2011 • 7 Comments
Low-Priced Biotech Stocks With Insider Buying
Rougemont • Fri, Mar 18, 2011 • 3 Comments
Biotech Deal Activity Takes a Breather
The Burrill Report • Sun, Apr 4, 2010
Antisoma Tumbles After Halting Cancer Trial: Biotech's Latest Mishaps
The Burrill Report • Sun, Apr 4, 2010 • 2 Comments

Dyax Corporation's CEO Discusses Q1 2013 Results - Earnings Call Transcript
Thu, Apr 25
Dyax's CEO Discusses Q4 2012 Results - Earnings Call Transcript
Wed, Feb 13
Dyax Corporation CEO Discusses Q3 2012 Results - Earnings Call Transcript
Wed, Oct 24, 2012
Dyax Corporation's CEO Presents at UBS Global Life Sciences Conference (Transcript)
Thu, Sep 20, 2012
Dyax Corporation CEO Discusses Q2 2012 Results - Earnings Call Transcript
Thu, Jul 19, 2012
Dyax's CEO Presents at Deutsche Bank AG Health Care Conference (Transcript)
Mon, May 7, 2012
Dyax Corporation CEO Discusses 3Q 2010 Results - Earnings Call Transcript
Thu, Oct 28, 2010
Dyax Corp. Q2 2010 Earnings Call Transcript
Wed, Jul 28, 2010
Dyax Corporation Q1 2010 Earnings Call Transcript
Sat, May 1, 2010
Dyax Q4 2009 Earnings Call Transcript
Wed, Feb 17, 2010
Dyax Corp. Q3 2009 Earnings Call Transcript
Wed, Oct 28, 2009
Dyax Corp. Q2 2009 Earnings Call Transcript
Wed, Jul 22, 2009
Dyax Q1 2009 Earnings Call Transcript
Wed, Apr 22, 2009
Dyax Corp. Q4 2008 Earnings Call Transcript
Wed, Feb 25, 2009
Dyax Corporation Q3 2008 Earnings Call Transcript
Tue, Nov 4, 2008
Dyax Corp. Q2 2008 Earnings Call Transcript
Wed, Jul 23, 2008

Dyax HAE Allies℠ Awards Program Launches on Second Annual Hereditary Angioedema (HAE) Day – a Global Event to Raise Awareness of HAE

Business Wire (Thu, 8:30AM)
Dyax Announces $30 Million Offering

Business Wire (May 13, 2013)
Dyax Corp. to Participate in the Needham Healthcare Conference

Business Wire (Apr 29, 2013)
Dyax Corp. Announces First Quarter 2013 Financial Results

Business Wire (Apr 25, 2013)
Dyax Corp. to Host First Quarter 2013 Earnings Call and Webcast

Business Wire (Apr 18, 2013)
Dyax Corp. to Participate in the 25th Annual ROTH Conference

Business Wire (Mar 12, 2013)
Dyax Announces Management Change

Business Wire (Mar 8, 2013)
Dyax Presents DX-2930 Data at the 2013 American Academy of Allergy, Asthma and Immunology Annual Meeting

Business Wire (Feb 25, 2013)
Dyax Corp. to Participate in Upcoming 2013 Healthcare Conferences

Business Wire (Feb 20, 2013)
Dyax Corp. Announces Fourth Quarter and Full Year 2012 Financial Results

Business Wire (Feb 13, 2013)
Dyax Corp. and CVie Therapeutics Announce Partnership to Develop and Commercialize KALBITOR® (ecallantide) for Hereditary Angioedema (HAE) and Other Angioedema Indications in China, Hong Kong and Macau

Business Wire (Feb 7, 2013)
Dyax Corp. to Participate in the Leerink Swann Global Healthcare Conference

Business Wire (Feb 6, 2013)
Dyax Corp. to Host Fourth Quarter and Year End 2012 Earnings Call and Webcast

Business Wire (Feb 5, 2013)
Dyax Corp. and Novellus Biopharma AG Announce Partnership to Develop and Commercialize KALBITOR® (ecallantide) for Hereditary Angioedema (HAE) and Other Angioedema Indications in Latin America

Business Wire (Jan 31, 2013)
Dyax Corp. Announces Presentation of KALBITOR® (ecallantide) Pediatric and Abdominal Attack Data at the American College of Allergy, Asthma and Immunology Annual Meeting (ACAAI)

Business Wire (Nov 13, 2012)
Dyax Corp. to Participate in November 2012 Healthcare Conferences

Business Wire (Nov 7, 2012)
Dyax Corp. Announces Third Quarter 2012 Financial Results

Business Wire (Oct 24, 2012)
Dyax Corp. to Host Third Quarter 2012 Earnings Call and Webcast

Business Wire (Oct 17, 2012)
Dyax Corp. Appoints Marc Kozin to Board of Directors

Business Wire (Oct 16, 2012)
Dyax Corp. and Kadmon Sign Strategic Licensing Agreement for DX-2400

Business Wire (Sep 20, 2012)

DYAX vs. ETF Alternatives

Company Description

We are a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel biotherapeutics for unmet medical needs, with an emphasis on inflammatory and oncology indications. We use our proprietary drug discovery technology, known as phage display, to... More

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, May 16, 5:41 PM After-hours top gainers, as of 5:15 p.m.: SINA +4.7%. EA +2.7%. NBG +2.5%. AKAM +2.4%. DYAX +2.4%.
After-hours top losers: ARUN -13.7%. ADSK -5.2%. BRCD -4.9%. JWN -3.5%. EGLE -2.4%. Comment! [On the Move]
Monday, May 13, 10:31 AM Dyax (DYAX +8.6%) pops this morning after pricing its approximately 8.9M shares registered direct offering with RA Capital, Venrock, Federated, and one other institutional investor at $2.30, nearly in line with Friday's close, for total gross proceeds of nearly $30M. Comment! [Healthcare, On the Move]
Friday, April 26, 1:32 PM Dyax (DYAX -33%) plummets today on a dismal Q1 report. Net sales came in at $8.6M, an increase over Q112 sales, but only about half of the $16.01M the Street expected. Net losses were $11.2M or $0.11 per share, relatively in line with Q112, but more than twice the $0.05 per share loss analysts expected. The company blames the miss on weak Kalbitor sales due to a decrease in the number of new patients added and a decline in the number of treatments among existing hereditary angioedema patients. Comment! [Healthcare, On the Move, Earnings]
Friday, April 26, 1:03 PM Midday top 10 gainers: LOGM +24%. LAS +17%. CTCT +16%. NR +15%. DQ +15%. WBSN +14%. QLIK +13%. CPGI +13%. SPWR +12%. CSIQ +12%.
Midday top 10 losers: DYAX -32%. HXM -23%. DLA -16%. IKAN -16%. KEG -15%. FALC -14%. COBR -13%. PKI -13%. XIDE -12%. MMSI -12%. Comment! [On the Move]
Thursday, April 25, 6:47 PM Dyax (DYAX): Q1 EPS of -$0.11 misses by $0.06. Revenue of $12M misses by $4.M. (PR) Comment! [Earnings, Breaking News]
Tuesday, March 5, 2:59 PM Shares of Dyax (DYAX +14.4%) pop today after Jefferies initiates the shares with a Buy rating and a $6 price target. Jefferies notes that with DYAX's wholly owned marketed orphan drug asset plus a widely partnered tech platform, the stocks makes an attractive small-cap biotech play. Additionally, long-term U.S. Kalbitor sales grow steadily, while royalties from potential Japan Kalbitor sales and U.S. ramucirumab sales across an increasing number of cancer indications provide additional growth catalysts. Comment! [Healthcare, On the Move]
Tuesday, March 5, 12:55 PM Midday top 10 gainers: ACUR +59%. HIMX +37%. MTG +25%. CREE +15%. APP +15%. ZOLT +15%. ASNA +14%. SNTS +14%. PKOH +14%. DYAX +13%.
Midday top 10 losers: IPXL -25%. RNIN -23%. DRWI -19%. REGI -17%. TELOZ -17%. SHIP -14%. CSUN -10%. SDT -10%. JCP -10%. PSTR -9%. Comment! [On the Move]
Wednesday, February 13, 6:47 PM Dyax (DYAX): Q4 EPS of -$0.05 in-line. Revenue of $16M beats by $1M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Monday, October 15, 2012, 12:45 PM Midday top 10 gainers: CYCC +40%. BCOM +35%. IGLD +24%. YONG +16%. EQS +15%. DYAX +14%. ALN +13%. BSDM +11%. CLWR +11%. ESYS +9%.
Top 10 Losers: DCTH -19%. PRWT -17%. DHRM -10%. AMED -9%. PLXT -9%. GROW -8%. IMOS -8%. HAUP -7%. ILMN -7%. DAC -7%. Comment! [On the Move]
Thursday, June 14, 2012, 4:29 PM Dyax (DYAX) -14% AH after declaring it will discontinue its Phase 2 trial for a drug meant to treat angiodema. Dyax says data from 72 patients taking part in the trials failed to produce a "statistically significant" difference in results for those taking its drug relative to those taking a placebo. Nonetheless, the company remains committed to broader angiodema drug development. Comment! [Healthcare, On the Move]
Monday, November 14, 2011, 4:57 PM Dyax (DYAX -7.3%) finishes the day lower after the company announced earlier today that it's decided to withdraw its Marketing Authorization Application filed with the European Medicines Agency for its heridary angiodema drug Kalbitor. Comment! [Healthcare, On the Move]
Thursday, March 25, 2010, 9:00 AM Premarket gainers: NIV +21%. CRXX +17%. CTIC +11%. SCLN +11%. CAAS +9%. CIGX +8%. LULU +8%. SLXP +7%. BBY +7%. PMI +6%. IRE +4%. MT +4%.
Losers: MELA -24%. ABK -18%. DYAX -5%. 1 Comment
Thursday, December 3, 2009, 9:00 AM Premarket gainers: ABK +18%. TPI +17%. PIR +9%. CYTR +7%. AIB +7%. TGB +6%. RYAAY +5%. THC +5%. MBI +4%. DLM +4%. DRYS +4%. BAC +3%.
Losers: PLCE -10%. ARO -8%. ENDP -9%. APWR -7%. SNPS -7%. ANF -7%. STEM -5%. DYAX -4%. Comment!
Wednesday, December 2, 2009, 9:00 AM Premarket gainers: SNTS +27%. DYAX +26%. KERX +14%. CYTR +14%. TSTR +7%. NVAX +7%. UAUA +5%. AMR +4%. RFMD +4%. HEAT +4%.
Losers: RBS -6%. RGNC -5%. ING -5%. DPTR -4%. Comment!
Monday, June 8, 2009, 9:21 AM Premarket gainers: PKT +102%. ANPI +56%. MITI +30%. DYAX +18%. SLM +14%. SVA +13%. ARNA +12%. XOMA +9%.
Losers: AIB -13%. LYG -11%. SAY -7%. MT -6%. Comment!

Ryan Mallory
Fuinhaz Setups for March 6 2013 $CLDX $DMND $DYAX $FB $FTR $GRPN $VOD $YHOO http://bit.ly/YcxeIe
Mar 6, 9:17 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Ryan Mallory
6 Stocks For Swing Trading That Are Gaining Momentum | $ATW is the best of them $ISRG $NUS $DYAX $XIN $JNJ http://bit.ly/QJx8Gr
10/15/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
4 Cash-Heavy Biotech Stocks That Analysts Rate As Strong Buy http://bit.ly/NWAqVP $BTX $DYAX $OPTR $SHP @ZetaKap
8/21/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Jim Van Meerten
DYAX - 24% Barchart technical sell signal - 14.81% down in the last month - Relative Strength Index 38.21%
8/13/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Jim Van Meerten
DYAX - 24% Barchart technical sell signal - 14.81% down in the last month - Relative Strength Index 38.21%
8/13/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
8 Biotechnology Stocks With Good Liquidity That Analysts Rate As Buy http://bit.ly/MxU9KJ $DYAX $CADX $BMRN $CYTX $CVM $AMGN $ALXN $CELG
5/25/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Chun Bong Lai
Watch out these symbols: AMCF, AGEN, CAPS.PK, CVM, CYTK. DYAX, BFLY, CLSN, CYBE, DGIT, DX
2/8/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

David White
DYAX up today on orphan drug approval by FDA. Fading in premarket. Some may be pushing it down to buy in regular market. Worth watching.
12/2/09
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

David White
DYAX is supposed to hear from the FDA today. Most expect a positive response. Orphan drug designation. FDA generally running behind in 2009.
12/1/09
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

DYAX Dyax Corp.

DYAX

Dyax Corp.